{"product_id":"legn-swot-analysis","title":"(LEGN) Legend Biotech Corporation SWOT Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Credibility Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Legend Biotech Corporation SWOT Analysis gives a concise, ready-made view of the company’s strengths, weaknesses, opportunities, and threats for strategic review, investment, or research. The content on this page is a genuine preview of the real report so you can judge format and depth before buying. Purchase the full version to download the complete, ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStrengths\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCARVYKTI commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCARVYKTI, Legend Biotech Corporation’s ciltacabtagene autoleucel with Janssen, is the company’s key de-risked asset and its clearest revenue engine, with annual sales already above $1 billion. A marketed CAR-T for multiple myeloma gives Legend Biotech Corporation proof of clinical, regulatory, and commercial execution that most biotech peers still lack. That cash flow also helps fund pipeline work and scale manufacturing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLate-stage multiple myeloma focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLCAR-B38M, or CARVYKTI, is Legend Biotech Corporation’s lead asset and a key strength in revlimid-refractory multiple myeloma, where CARTITUDE-4 cut the risk of progression or death by 74% versus standard triplet therapy. Multiple myeloma still has high unmet need, and CARVYKTI generated about $963 million in global sales in 2024, showing strong commercial pull. That efficacy and safety profile can support durable adoption and reinforces Legend Biotech Corporation’s leadership in plasma-cell cancers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad oncology pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation has a broad oncology pipeline with multiple autologous CAR-T candidates in gastric cancer, T-cell lymphoma, non-Hodgkin’s lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. That spread covers both hematologic and solid tumors, so the Company is not tied to one disease area. In 2025, its lead asset CARVYKTI generated $1.96 billion in net product sales, showing the platform can already scale while new shots on goal remain in play.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal operating footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s footprint across the United States, China, and international markets gives it access to larger patient pools, more trial sites, and wider launch routes. That matters for CARVYKTI, which generated $963 million in global sales in 2024, showing how cross-border reach can turn clinical progress into revenue faster. A base in more than one region also reduces reliance on any single market and supports broader future penetration.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS, China, and global reach\u003c\/li\u003e\n\u003cli\u003eMore trial sites and patients\u003c\/li\u003e\n\u003cli\u003eFaster path to launches\u003c\/li\u003e\n\u003cli\u003eLess single-market dependence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eJanssen collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s long-term Janssen partnership gives it deep financial, regulatory, and launch support, which matters in a complex cell therapy business. The deal included a $350 million upfront payment and up to $3.5 billion in milestone potential, reducing solo execution risk. It also broadens manufacturing and market access, making Legend Biotech Corporation stronger than smaller standalone developers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJanssen lowers execution risk.\u003c\/li\u003e\n\u003cli\u003eManufacturing reach is wider.\u003c\/li\u003e\n\u003cli\u003eCommercial access is stronger.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCARVYKTI Drives Legend Biotech’s Commercial Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s main strength is CARVYKTI, which generated $1.96 billion in net product sales in 2025 and gives the Company real commercial scale. CARTITUDE-4 cut progression or death risk by 74%, supporting a strong clinical edge in multiple myeloma. The Janssen partnership also lowers execution risk and expands reach.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCARVYKTI sales\u003c\/td\u003e\n\u003ctd\u003e$1.96B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCARTITUDE-4 efficacy\u003c\/td\u003e\n\u003ctd\u003e74% risk reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear SWOT framework for analyzing Legend Biotech Corporation’s business strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise Legend Biotech SWOT snapshot to quickly clarify risks, strengths, and strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of primary industry reports, regulatory filings, and peer-reviewed data to speed due diligence and validate Legend Biotech assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eWeaknesses\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation still has most of its pipeline in clinical or preclinical stages, so its value depends heavily on trial wins, faster enrollment, and FDA and EMA reviews. With only one marketed therapy, CARVYKTI, cash generation still leans on a narrow base, while clinical biopharma programs can take 7 to 10 years and often fail before approval.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-asset dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation still leans heavily on CARVYKTI, its lead multiple myeloma CAR-T, which has driven most of its revenue run rate. That single-asset exposure is a real weakness: if uptake or durability disappoints, the hit to valuation and strategy could be sharp. The broader pipeline is growing, but it is still less proven than the franchise that carries the business.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutologous complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s autologous cell therapy model makes each dose patient-specific, so one failed batch can delay treatment for 1 patient and disrupt the whole schedule. This raises quality and logistics risk, and it also limits scale versus off-the-shelf biologics. That complexity can pressure turnaround times, access, and margins even as demand rises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEarly solid tumor exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s solid tumor work is still early, so it does not yet offset dependence on hematologic cancer sales. Solid tumors are tougher in cell therapy because the tumor microenvironment blocks T-cell activity and poor trafficking limits tumor penetration. That leaves high clinical risk, and success in blood cancers has not translated cleanly into this area yet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly-stage pipeline\u003c\/li\u003e\n\u003cli\u003eHigh biological risk\u003c\/li\u003e\n\u003cli\u003eNo commercial buffer yet\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnered economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s Janssen partnership limits standalone upside on CARVYKTI because economics are shared, so the company does not keep 100% of the franchise value. That tradeoff matters: Johnson \u0026amp; Johnson reported CARVYKTI net sales of $963 million in 2024, but Legend captures only part of that pool. The deal cuts risk and funding needs, yet it also caps control and the full profit it could earn alone.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShared economics trim upside.\u003c\/li\u003e\n\u003cli\u003ePartner controls key decisions.\u003c\/li\u003e\n\u003cli\u003eRisk falls, but returns cap.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegend Biotech’s CARVYKTI Dependence Limits Growth and Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation remains weakly diversified: CARVYKTI still anchors most revenue, so any slowdown hits hard. Its pipeline is still early, and autologous CAR-T manufacturing adds batch risk, slower scale, and higher costs. The Janssen deal also caps upside, since Legend does not keep all CARVYKTI economics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingle-asset reliance\u003c\/td\u003e\n\u003ctd\u003eCARVYKTI sales were $963 million in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShared economics\u003c\/td\u003e\n\u003ctd\u003eJanssen limits full profit capture\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eLegend Biotech Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Legend Biotech SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality; the preview below is pulled directly from the full report and the complete, editable version becomes available immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eOpportunities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiple myeloma expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMultiple myeloma is a large, recurring market, with about 36,000 new U.S. cases a year, so Legend Biotech Corporation can extend its CAR-T platform into earlier treatment lines and widen patient reach. More label expansion could lift CARVYKTI use beyond later-line care, while longer follow-up and stronger survival data should help physician adoption and support higher revenue over time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCD19 CD20 CD22 programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation's CD19, CD20, and CD22 CAR-T programs tap large B-cell malignancy markets, where CAR-T is already a multi-billion-dollar heme-onc category in 2025. These targets have clear clinical demand because CD19 is validated, while CD20 and CD22 can help address resistance and relapse. Success in even one program would widen the pipeline and cut reliance on the multiple myeloma franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSolid tumor entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s solid-tumor pipeline is a high-upside bet: solid tumors make up about 90% of adult cancers, so even modest clinical progress could open a far larger market than blood cancers alone. In FY2025, CARVYKTI had already given Legend a strong cash base, with global sales above $1 billion, helping fund these longer-dated programs. A real breakthrough here would be strategically material, not just incremental.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational market growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation already sells in the U.S., China, Europe, and Japan, so it has a base for wider CAR-T launches. CARVYKTI generated about $1.0 billion in 2024 sales, showing that global demand is real while cell therapy use is still early in many markets.\u003c\/p\u003e\n\u003cp\u003eMore approvals could lift reach fast, and cross-border supply can be a moat if Legend Biotech Corporation keeps scaling manufacturing and logistics across regions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S., China, EU, Japan footprint\u003c\/li\u003e\n\u003cli\u003eCARVYKTI: about $1.0B in 2024\u003c\/li\u003e\n\u003cli\u003eEarly cell therapy adoption, room to expand\u003c\/li\u003e\n\u003cli\u003eMore approvals can widen sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStrategic partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrategic partnerships let Legend Biotech Corporation speed development and commercialization while sharing the heavy cost of cell therapy work, which can run into the hundreds of millions before launch. Its Janssen alliance already helped CARVYKTI reach more than $1 billion in annual sales in 2025, showing how partners can expand market access fast. New deals can also add manufacturing capacity and lower risk as Legend Biotech moves beyond oncology.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFaster development with shared cost\u003c\/li\u003e\n\u003cli\u003eBroader market access through partners\u003c\/li\u003e\n\u003cli\u003eManufacturing support for cell therapy scale\u003c\/li\u003e\n\u003cli\u003eLower risk in new non-oncology areas\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegend Biotech’s CARVYKTI Growth Engine Still Has Room to Run\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s biggest upside is deeper CARVYKTI penetration in multiple myeloma: FY2025 sales topped $1.0B, and earlier-line use could expand the addressable pool. Its U.S., China, EU, and Japan footprint also gives it room to scale approvals, while CD19\/CD20\/CD22 and solid-tumor programs offer pipeline diversification beyond one franchise.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCARVYKTI expansion\u003c\/td\u003e\n\u003ctd\u003eFY2025 sales \u0026gt;$1.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic growth\u003c\/td\u003e\n\u003ctd\u003eU.S., China, EU, Japan\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline diversification\u003c\/td\u003e\n\u003ctd\u003eCD19\/CD20\/CD22, solid tumors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eThreats\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCAR-T competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCAR-T competition is intense in multiple myeloma and lymphoma, where Legend Biotech Corporation faces larger rivals with similar cell therapies and non-cell options. As of 2025, BCMA and CD19 markets already include approved CAR-Ts plus several bispecifics, so rivals can still win on safety, one-time dosing, or faster access. That can cap CARVYKTI demand even after its 2024 sales reached $1.08 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCAR-T manufacturing is a fragile chain: one patient’s cells must be collected, processed, tested, and shipped on time. The FDA has approved only 7 CAR-T therapies in the U.S., so any quality slip can delay treatment, trigger recalls, or invite closer regulatory review. For Legend Biotech Corporation, even small batch failures can hurt both patient access and commercial consistency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory scrutiny\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegulatory scrutiny is a real threat for Legend Biotech Corporation because CARVYKTI carries a REMS and 15-year long-term follow-up requirement, reflecting class risks like CRS, neurotoxicity, and rare delayed events. Any new safety signal can trigger post-marketing commitments, label limits, or slower approvals, which can curb uptake in a market where treatment decisions are already cautious. That risk matters when CARVYKTI is already on the market, because one adverse event can affect both sales and future pipeline reviews.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePricing pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePricing pressure is a real threat for Legend Biotech Corporation because CAR-T drugs like CARVYKTI can face payer pushback on high upfront costs, which in the U.S. can be about $465,000 per infusion. Even after FDA approval, reimbursement reviews and prior authorization can delay access, and cost-effectiveness talks get tougher as more cell therapies compete. That can slow uptake and squeeze margins, especially when hospitals and government systems demand proof of value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh upfront CAR-T pricing invites payer pushback\u003c\/li\u003e\n\u003cli\u003eReimbursement delays can block patient access\u003c\/li\u003e\n\u003cli\u003eMore rivals can intensify price and value scrutiny\u003c\/li\u003e\n\u003cli\u003eSlower adoption can pressure margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical failure risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical failure is a real threat for Legend Biotech Corporation because its early programs in gastric cancer, T-cell lymphoma, solid tumors, and infectious diseases still need to clear late-stage trials. Across biopharma, only about 1 in 10 drug candidates that enter Phase I reach approval, and oncology success rates are even lower. Any setback would cut pipeline value and can hit investor confidence fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh attrition can erase early promise.\u003c\/li\u003e\n\u003cli\u003eApproval odds stay low in oncology.\u003c\/li\u003e\n\u003cli\u003eFuture growth depends on trial wins.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor Legend Biotech Corporation, the risk is simple: promising biology does not equal approved therapy. If late trials miss endpoints or show safety issues, future revenue expectations can drop sharply.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCARVYKTI’s Growth Faces Rising Competition, Safety, and Payer Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation faces heavy competition in BCMA and CD19, plus payer pressure on CARVYKTI’s high upfront cost. Any FDA safety signal, REMS tightening, or manufacturing slip could slow access and raise costs. Pipeline risk is still high: oncology attrition stays steep, so late-stage misses can quickly erase growth. CARVYKTI sales reached $1.08 billion in 2024, but that scale also draws tougher scrutiny.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetition\u003c\/td\u003e\n\u003ctd\u003eApproved CAR-Ts and bispecifics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePricing\u003c\/td\u003e\n\u003ctd\u003e~$465,000 per infusion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety\u003c\/td\u003e\n\u003ctd\u003eREMS, 15-year follow-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales\u003c\/td\u003e\n\u003ctd\u003eCARVYKTI $1.08B in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234686902537,"sku":"legn-swot-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/legn-swot-analysis.webp?v=1785723662","url":"https:\/\/dcfanalyst.com\/products\/legn-swot-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}